The commencement of the Phase IIa trial evaluating RPL554 as an add-on therapy to tiotropium is encouraging and in line with expectations. Top line data is expected in Q4 2017. In 2017 we also expect the group to commence and report top line data from a Phase IIa trial in Cystic Fibrosis, to commence a Phase IIb 4-week dose-ranging trial in COPD and undertake a NASDAQ listing. We remain upbeat about Verona Pharma’s future prospects and look forward to its development updates during the year.
22 Feb 2017
N+1 Singer - Verona Pharma - Phase IIa RPL554 add-on trial to tiotropium commenced
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Verona Pharma - Phase IIa RPL554 add-on trial to tiotropium commenced
Verona Pharma plc Sponsored ADR (VRNA:NAS) | 0 0 0.0%
- Published:
22 Feb 2017 -
Author:
Sheena Berry -
Pages:
3
The commencement of the Phase IIa trial evaluating RPL554 as an add-on therapy to tiotropium is encouraging and in line with expectations. Top line data is expected in Q4 2017. In 2017 we also expect the group to commence and report top line data from a Phase IIa trial in Cystic Fibrosis, to commence a Phase IIb 4-week dose-ranging trial in COPD and undertake a NASDAQ listing. We remain upbeat about Verona Pharma’s future prospects and look forward to its development updates during the year.